ANTX compared with SABS: revenue, margins and what each company keeps, and the suppliers and customers both name

ANTXAN2 Therapeutics, Inc.

Mkt capRevenueRevenue

SABSSAB Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

ANTXAN2 Therapeutics, Inc.

SABSSAB Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ANTX 0

None

Shared 0

No disclosed counterparties: ANTX.

Only SABS 5

EBSEmergent BioSolutions Canadasupplier

—Avance Clinical PTY, Ltd ("Avance")unlistedsupplier

—Fortrea Holdings Inc. ("Fortrea")unlistedsupplier

—Sanford Applied Biosciencesunlistedsupplier

1 more · SABS chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

ANTXAN2 Therapeutics, Inc.

4.00▲+1.14%· post 4.00

Mkt cap$149.2MRevenue—

SABSSAB Biotherapeutics, Inc.

3.02▲+2.59%· post 3.02

ClosedNov 6 '26

Mkt cap$273.0MRevenue$114,698Q4 FY24

Compare

ClosedNov 6 '26

ANTXAN2 Therapeutics, Inc.

SABSSAB Biotherapeutics, Inc.

4.00▲+1.14%post 4.00

Price

3.02▲+2.59%post 3.02

$149.2M

Mkt cap

$273.0M

—

Revenue

$114,698Q4 FY24

ANTX4.00▲+1.14%vsSABS3.02▲+2.59%ClosedNov 6 '26